Pain Reduction With Oral Methotrexate in Knee Osteoarthritis
Уменьшение боли при остеоартрите коленного сустава при пероральном применении метотрексата
2024-07-29
SCID: 54.1/n4nzb5ys
Discuss with AI
knee osteoarthritisknee painnumerical rating scaleoral methotrexaterandomized placebo-controlled trial
Figures from the paper
Abstract (AI)
BACKGROUND: Treatments for osteoarthritis (OA) are limited. Previous small studies suggest that the antirheumatic drug methotrexate may be a potential treatment for OA pain. OBJECTIVE: To assess symptomatic benefits of methotrexate in knee OA (KOA). DESIGN: A multicenter, randomized, double-blind, placebo-controlled trial done between 13 June 2014 and 13 October 2017. (ISRCTN77854383; EudraCT: 2013-001689-41). SETTING: 15 secondary care musculoskeletal clinics in the United Kingdom. PARTICIPANTS: A total of 207 participants with symptomatic, radiographic KOA and knee pain (severity ≥4 out of 10) on most days in the past 3 months with inadequate response to current medication were approached for inclusion. INTERVENTION: Participants were randomly assigned 1:1 to oral methotrexate once weekly (6-week escalation 10 to 25 mg) or matched placebo over 12 months and continued usual analgesia. MEASUREMENTS: The primary end point was average knee pain (numerical rating scale [NRS] 0 to 10) at 6 months, with 12-month follow-up to assess longer-term response. Secondary end points included knee stiffness and function outcomes and adverse events (AEs). RESULTS: = 0.008). Treatment adherence analysis supported a dose-response effect. Four unrelated serious AEs were reported (methotrexate: 2, placebo: 2). LIMITATION: Not permitting oral methotrexate to be changed to subcutaneous delivery for intolerance. CONCLUSION: Oral methotrexate added to usual medications demonstrated statistically significant reduction in KOA pain, stiffness, and function at 6 months. PRIMARY FUNDING SOURCE: Versus Arthritis.
Key Findings
1
A multicenter randomized, double-blind, placebo-controlled trial evaluated weekly oral methotrexate for symptomatic knee osteoarthritis over 12 months.
2
Four unrelated serious adverse events occurred, with two in the methotrexate group and two in the placebo group.
3
Oral methotrexate added to usual analgesia produced statistically significant improvements in knee pain, stiffness, and function at 6 months.
4
The trial did not permit switching to subcutaneous methotrexate for intolerance, limiting management of oral-treatment intolerance.
5
Treatment-adherence analysis supported a dose-response relationship for methotrexate’s symptomatic benefits.
Research Object
symptomatic, radiographic knee osteoarthritis with persistent knee pain
Research Subject
the effects of oral methotrexate on knee osteoarthritis pain, stiffness, and function
Publication Details
Publication Date
2024-07-29
Journal
Publisher
ISSN
Cited by
47
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by6
Osteoarthritis year in review 2025: Epidemiology and therapy2025
Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial2025
Targeting Inflammation in Osteoarthritis Pain: A Phenotype-Driven Approach2026
Systemic biomarkers of treatment response to methotrexate in people with painful knee osteoarthritis: A biological substudy of the PROMOTE randomised controlled clinical trial2026
The effectiveness and safety of methotrexate in the intervention of osteoarthritis: A systematic review and meta-analysis of randomized controlled trials2025
Methotrexate for the treatment of osteoarthritis: a systematic review and meta-analysis of randomized controlled trials2025